Novartis stock popped Thursday — prompting Travere Therapeutics to slide — after winning FDA approval for a kidney disease treatment.

BofA analyst Jason Zemansky lowered the firm’s price target on Travere Therapeutics (TVTX) to $27 from $31 and keeps a Buy rating on the shares ...

When Novartis bought kidney disease biotech Chinook Therapeutics in 2023 for $3.2 billion upfront, the deal included a ...

Travere Therapeutics (NASDAQ:TVTX – Get Free Report)‘s stock had its “overweight” rating reiterated by equities research analysts at Cantor Fitzgerald in a research report issued to clients and ...

In a report released yesterday, Vamil Divan from Guggenheim reiterated a Buy rating on Travere Therapeutics (TVTX – Research Report), with a ...

Travere Therapeutics (NASDAQ:TVTX – Free Report) had its price target increased by Bank of America from $29.00 to $31.00 in a report issued on Tuesday,Benzinga reports. Bank of America currently has a ...

Ratings for Travere Therapeutics TVTX were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview of ...

Vanrafia (atrasentan) is the first drug in the selective endothelin A receptor antagonist (ERA) class to be cleared in the US ...

Travere's late-breaking oral presentation at NKF details partial and complete proteinuria remission data from the DUPLEX Study of FILSPARI in FSGS ...

sNDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare ...